US008927552B2
`
`a2) United States Patent
`US 8,927,552 B2
`(10) Patent No.:
`
`(45) Date of Patent: Jan. 6, 2015
`Batheet al.
`
`(54) POLYMORPHIC FORMSOF1-[4-(5-
`CYANOINDOL-3-YL)BUTYL]-4-(2-
`CARBAMOYLBENZOFURAN-5-YL)
`PIPERAZINE HYDROCHLORIDE
`
`8,236,804 B2
`8,318,744 B2
`8,673,921 B2
`2011/0183994 Al
`2011/0294824 Al
`
`8/2012 Batheetal.
`11/2012 Bathe etal.
`3/2014 Batheetal.
`7/2011 Batheetal.
`12/2011 Bathe etal.
`
`(71) Applicant: Merck Patentgesellschaft, Darmstadt
`(DE)
`
`FOREIGN PATENT DOCUMENTS
`
`(72)
`
`4/1995
`0648767 Al
`EP
`Inventors: Andreas Bathe, Darmstadt (DE); Bernd
`10/1996
`0738722 Al
`EP
`Helfert, Ober-Ramstadt (DE); Steffen
`12/2000
`00/72832 A2
`WO
`Neuenfeld, Messel (DE); Heike Kniel,
`
`WO 02/102794 A2=12/2002
`Heppenheim (DE); Matthias Bartels,
`Darmstadt (DE); Susanne Rudolph,
`Dieburg (DE); Henning Béttcher,
`Darmstadt (DE)
`
`(73) Assignee: Merck Patentgesellschaft, Darmstadt
`(DE)
`
`(*) Notice:
`
`Subject to any disclaimer, the term ofthis
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`
`(21) Appl. No.: 13/658,088
`
`(22)
`
`(65)
`
`Filed:
`
`Oct. 23, 2012
`
`Prior Publication Data
`
`US 2013/0102616 Al
`
`Apr. 25, 2013
`
`Related U.S. Application Data
`
`(60) Continuation of application No. 13/085,117, filed on
`Apr. 12, 2011, now Pat. No. 8,318,744, which is a
`continuation of application No. 12/566,835, filed on
`Sep. 25, 2009, now Pat. No. 7,981,894, which is a
`division of application No. 12/110,704,filed on Apr.
`28, 2008, now Pat. No. 7,834,020, which is a division
`of application No. 10/481,270,filed as application No.
`PCT/EP02/06153 on Jun. 5, 2002, now Pat. No.
`7,381,726.
`
`(30)
`
`Foreign Application Priority Data
`
`Jun. 19,2001
`
`(EP) eee ceeeeneeecenee 01113674
`
`(51)
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. Cl.
`AGIK 31/496
`CO7D 403/14
`CO7D 405/14
`CO7D 405/12
`(52) U.S. CL.
`CPC wee CO7D 405/14 (2013.01); A6LK 31/496
`(2013.01); CO7D 405/12 (2013.01)
`USPC iecesesesctsesseesenstetscnssenees 514/254.09; 544/373
`(58) Field of Classification Search
`USPC iecesesesctsesseesenstetscnssenees 514/254.09; 544/373
`See application file for complete search history.
`
`(56)
`
`References Cited
`U.S. PATENT DOCUMENTS
`
`5,521,241 A
`5,532,241 A
`5,723,614 A
`5,977,112 A
`7,381,726 B2
`7,834,020 B2
`7,981,894 B2
`8,193,195 B2
`
`5/1996 Wu
`7/1996 Bottcheret al.
`3/1998 Bathe etal.
`11/1999 Batheet al.
`6/2008 Bathe etal.
`11/2010 Batheetal.
`7/2011 Batheet al.
`6/2012 Batheet al.
`
`OTHER PUBLICATIONS
`
`Summary ofFacts Regarding US ClinicalTrials Prior to Jun. 5, 2001.
`Sorbera, L.A. et al. “Vilazodone Hydrochloride. Antidepressant
`5-HT .sub.1A Partial Agonist 5-HT Reuptake Inhibitor” Drugsofthe
`Future 2001, 26(3):247-252. (Mar. 2001).
`Remington Farmacia Tomo 2 19.sup.a edicion. (1998).
`Farmacotecnia TeoricaY Practica TomoiV, Dr. Jose Heiman. (1980).
`Hungarian Search Report of May 10, 2010, citing HU P0201275
`which corresponds to WO 00/72832.
`Office Action for U.S. Appl. No. 12/945,260, date ofmailing Aug. 17,
`2011.
`Office Action for U.S. Appl. No. 12/945,272, date ofmailing Aug. 17,
`2011.
`Office Action for U.S. Appl. No. 13/100,911, date of mailing Nov.9,
`2011.
`Office Action for U.S. Appl. No. 13/085,117, date of mailing Jan. 13,
`2012.
`Notice of Allowance for U.S. Appl. No. 12/945,272, date of mailing
`Mar. 19, 2012.
`Corrected Notice of Allowance for U.S. Appl. No. 12/945,272, date
`of mailing Apr. 3, 2012.
`Office Action for U.S. Appl. No. 13/100,911, date ofmailing Mar.23,
`2012.
`Office Action for U.S. Appl. No. 13/100,911, date ofmailing Aug. 17,
`2012.
`Office Action for U.S. Appl. No. 13/085,117, date of mailing Apr. 3,
`2012.
`
`(Continued)
`
`Primary Examiner — Samantha Shterengarts
`(74) Attorney, Agent, or Firm — McCarter & English, LLP;
`Daniell L. Herritt; Jin Wang
`
`(57)
`
`ABSTRACT
`
`The invention relates to new crystalline modifications of the
`hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl|-4-(2-car-
`bamoyl-benzofuran-5-yl)-piperazine, crystalline modifica-
`tion of the dihydrochloride of 1-[4-(5-cyanoindol-3-yl)bu-
`tyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine
`and
`amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-
`benzofuran-5-yl)-piperazine hydrochloride which are suit-
`able in particular for the preparation of solid medicaments for
`the treatment or prevention of depressive disorders, anxiety
`disorders, bipolar disorders, mania, dementia, substance-re-
`lated disorders, sexual dysfunctions, eating disorders, obe-
`sity, fibromyalgia, sleeping disorders, psychiatric disorders,
`cerebral infarct, tension, for the therapy of side-effects in the
`treatment ofhypogonadism, secondary amenorrhea, premen-
`strual syndrome and undesired puerperallactation.
`
`11 Claims, 23 Drawing Sheets
`
`Merck 2021
`Argentum v. Merck
`IPR2018-00423
`
`Merck 2021
`Argentum v. Merck
`IPR2018-00423
`
`

`

`US 8,927,552 B2
`
`Page 2
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`Notice of Allowance for U.S. Appl. No. 13/085,117, date of mailing
`Aug. 17, 2012.
`Office Action for U.S. Appl. No. 13/100,948, date ofmailing Nov. 18,
`2011.
`
`Office Action for U.S. Appl. No. 13/100,948, date ofmailing Mar. 27,
`2012.
`Notice of Allowance for U.S. Appl. No. 13/100,948, date of mailing
`Jun. 4, 2012.
`Morissette et al. Advanced Drug Delivery Reviews, 2004, 56:275-
`300.
`Notice of Allowance for U.S. Appl. No. 14/032,183, date of mailing
`Dec. 13, 2013.
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 1 of 23
`
`US 8,927,552 B2
`
`oa
`
`
`
`ABSORBANCEUNITSOo9Ww+
`
`©No
`
`oin
`
`4000
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`WAVENUMBER cmm-1
`
`Fig. 1
`
`Form II
`
`2an
`
`Ooin
`
`
`
`ABSORBANCEUNITSo9°a+
`
`©iw
`
`0.1
`
`0.0
`4000
`
`
`!
`——
`!
`2500
`2000
`1500
`
`3500
`
`3000
`
`1000
`
`500
`
`WAVENUMBER cm-1
`
`Fig. 2
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 2 of 23
`
`US 8,927,552 B2
`
`Form XV
`
` [o)co
`
` lita\W \!eaay
`
`i
`
`wi
`1000
`
`500
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`WAVENUMBER cm-1
`
`Fig. 3
`
`oOOV
`
`
`
`ABSORBANCEUNITS °
`
`o o 2
`
`0.02
`
`0.00
`
`”
`a
`
`0.4
`50.3
`Lu
`z
`VY
`cB 0.2
`O
`A
`<
`
`0.1
`
`|
`
`0.042%
`
`.
`
`T
`3000
`
`T
`2500
`
`a
`i
`
`j
`
`|
`
`
`
`|
`i
`|
`i
`OER
`Hei
`HEE
`cel
`i
`mew
`|
`Py ay
`| rl
`I
`\
`i
`\
`|
`|
`WA
`|
`| |
`/
`PY
`
`Y
`.
`3500
`1500
`
`Form XI
`
`ii
`
`2000
`
`Te
`
`WAVENUMBER cm-1
`
`Fig. 4
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 3 of 23
`
`US 8,927,552 B2
`
`0.14
`
`Form XIV
`
`0.12
`
`oOOooOay©oO
`
`
`
`ABSORBANCEUNITS °ro
`
`0.04
`
`
`
`T
`
`3500
`
`T
`
`3000
`
`T
`
`2500
`
`LL
`
`2000
`
`T
`
`1500
`
`T
`
`1000
`
`T
`
`500
`
`WAVENUMBER cm-1
`
`Fig. 5
`
`Form V
`
`0.02
`
`0.00
`
`2.0
`
`
`
`ABSORBANCEUNITS °in
`
`oun
`
`0.0
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`WAVENUMBER cm-1
`
`Fig. 6
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 4 of 23
`
`US 8,927,552 B2
`
`Form VI
`
`
`
`ABSORBANCEUNITS
`
`0.44
`
`0.34
`
`0.2
`
`0.1-
`
`
`
`O.O-rirIN"ewuoo3000az00adoo~00doo3000 2500 2000 1500 1000
`
`iw 0.5
`0.05-
`
`
`
`
`
`
`
`
`
`0.20-
`
`oS — v
`
`
`
`ABSORBANCEUNITS ° 2
`
`WAVENUMBER cm-1
`
`Fig. 7
`
`0.25-
`
`Form VIII
`
`j
`
`T
`3500
`
`0.00-#re!
`
`T
`
`3000
`
`T
`
`2500
`
`T
`
`2000
`
`T
`
`1500
`
`1000
`
`T
`
`500
`
`WAVENUMBER cm-1
`
`Fig. 8
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 5 of 23
`
`US 8,927,552 B2
`
`Form IV
`
`2S2ww5
`ABSORBANCEUNITS ° Na
`
`
`
`0.1
`
`0.0
`4000
`
`0.5
`
`
`
`ABSORBANCEUNITS©ooONoiwiS
`
`Oo ou
`
`0.0
`4000
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`WAVENUMBER cm-1
`
`Fig. 9
`
`Form III
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`—
`
`WAVENUMBER cm-1
`
`Fig. 10
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 6 of 23
`
`US 8,927,552 B2
`
`|
`
`FormVII
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`WAVENUMBER cm-1
`
`Fig. 11
`
`Form I
`
`UNITS ° 0.00-==
`oABSORBANCE
`
`
`Wdvenicethenncancean
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 12
`
`0.20
`
`8000-
`
`g3g
`
`o 4000-
`&—_l
`
`0
`
`1
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 7 of 23
`
`US 8,927,552 B2
`
`Form II
`
`|
`
`8000+
`
`7000-4
`
`6000-
`
`i
`
`
`
`
`
`
`# s000-
`=
`
`8anonN |
`
`9 40004\
`|
`= 30001 \
`ly |
`|
`|
`2000-
`SY (I cu
`4
`afl hy i | |
`WOON Ua
`4
`.
`1000-
`WMI
`|
`Se WAaesPanihoa,ALA.MensDacecence
`
`1
`
`10
`
`20
`
`30
`
`40
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 13
`
`Form XV
`
`1 OAaegnreatetven
`
`
`Ot
`1
`10
`20
`30
`40
`50
`60
`
`Kany
`
`2-Theta - Scale
`
`Fig. 14
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 8 of 23
`
`US 8,927,552 B2
`
`Form X
`
`|
`
`8000
`
`4000
`
`2
`
`>}
`
`UY
`
`&—
`
`Meetcttet
`
`0TTI
`1
`10
`20
`30
`40
`50
`60
`
`2-Theta - Scale
`
`Fig. 15
`
`Form XI
`
`6000
`
`@ 4000
`
`c5} Y &—
`
`|
`2000
`NUNrtAena
`
`0
`
`2-Theta - Scale
`
`Fig. 16
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 9 of 23
`
`US 8,927,552 B2
`
`Form XIV
`
`by“MyAyo{,
`
` 1
`
`30
`
`40
`
`50
`
`60
`
`10
`
`20
`
`2-Theta - Scale
`
`Fig. 17
`
`Form V
`
`Lin(Counts)
`
`
`
`
`
`20
`
`30
`
`40
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 18
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 10 of 23
`
`US 8,927,552 B2
`
`Form VI
`
`12000-
`11000-
`10000-
`9000-|
`|8000+
`€ 7000-
`© 60004
`= 5000-
`4000-|
`3000-
`2000-
`1000-|
`
`1
`
`2-Theta - Scale
`
`Fig. 19
`
`Form VIII
`
` 0
`nh al
`0 a
`
`17000-
`16000-
`15000-
`14000-
`13000-
`12000-
`=11000-
`=10000-
`3 9000-
`Y g000-
`= 7000-
`6000-
`5000-
`4000
`3000-
`2000-1
`1000-
`
`
`
`hl \\' Nukbeediecenia
`
`10
`
`20
`
`30
`
`40
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 20
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 11 of 23
`
`US 8,927,552 B2
`
`Form IV
`
`
`0 Brennenattedpee”
`1
`10
`20
`30
`40
`50
`60
`
`
`
`2-Theta - Scale
`
`Fig. 21
`
`Form III
`
` BhLl hin.
`
`
`
` Lin(Counts)
`
`|
`
`baPOPee
`
`0ee
`1
`10
`20
`30
`40
`50
`60
`
`2-Theta - Scale
`
`Fig. 22
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 12 of 23
`
`US 8,927,552 B2
`
`Form VII
`
`2-Theta - Scale
`
`Fig. 23
`
`Form IX
`
`600
`
`Lin(Counts)
`
`Ww ooO
`
`N SooO
`
`100
`
` 1
`
`10
`
`20
`
`30
`
`40
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 24
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 13 of 23
`
`US 8,927,552 B2
`
`Form XIII
`
`900-4
`
`800-1
`
`700-4
`
` 600-
`c
`4
`3 500-
`Y
`J
`
`
`
`Wernenligretinntlaneiseateday
`
`300-
`
`5 400-
`2004seth
`asa
`100"
`
`7 NganSUwtlSnPacempeelrare
`
`0
`
`1
`
`10
`
`20
`
`30
`
`40
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 25
`
`Form XVI
`
`3000
`
`¥ Leaeaetjh
`
`1
`
`10
`
`20
`
`30
`
`40
`
`50
`
`60
`
`2-Theta - Scale
`
`Fig. 26
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 14 of 23
`
`US 8,927,552 B2
`
`ENERGY/TEMPERATURE DIAGRAM (SCHEMATIC)
`
`| é
`
`ENERGY4
`
`een
`
`t Lceeenenee
`
`WV vecesoes
`ty
`
`Ay
`“Hi
`
`Gy
`Giy
`
`Gy)
`
`0
`
`Tiny
`
`Theva Tiyevi nit Tinvil TEMPERATURE
`Tin IV
`
`
`
`170
`161.92°C
`247.27°C 283.88°C
`L
`78.04J)/g
`1.324)/g 107.5J/g
`145
`
`
`
`
`243.22°C
`234,93°C
`r
`
`
`4,600(3.276)J/g
`1120
`
`170.89°C
`re
`
`10.60%
`t
`
`(0.1639mq)
`lo5 a
`
`
`t
`=
`[
`L
`
`-70
`
`Fig. 27
`
`290,.28°C
`
`L45
`
`
`pensef
`
`
`
`0
`
`_
`orl
`=
`=
`Q-2
`i
`fe
`Lu
`=I -3
`
`-4
`
`
`
`Bo 20
`50
`75
`100 125 150 175 200 225 250 275 300
`325 350 375 400
`
`TEMPERATURE (°C)
`EMD 68843 FORM | (ACETONE SOLVATE)
`Fig. 28
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 15 of 23
`
`US 8,927,552 B2
`
`
`
`150
`1-4
`
`7 223.47°C=:291.61°C°
`
`0+
`7a40N/g
`1.966)/g
` 107.4J/g
`
`
`:
`
`
`-1-
`233.33°C
`_ 5!
`154.20°C
`
`
`=
`= |
`13.26%
`3 3
`
`Z 4
`(1.595mq)
`s
`|
`
`140
`
`130
`
`120
`110 3
`_
`100 =
`90
`80
`
` 40
`
`0
`
`
`
`Tr -5-4
`4
`-6-
`|
`74
`
`293.31°C
`
`70
`
`60
`50
`
`50
`
`75)
`
`«6100
`
`125
`
`150
`
`175 200 225 250 275 300 325 350
`
`Exo Up
`
`TEMPERATURE(°C)
`EMD 68843 FORM II (THF SOLVATE)
`Fig. 29
`
`UNIVERSALV2.4F TA
`INSTRUMENTS
`
`Oo
`
`o7150
`t
`288.02°C
`L140
`131.2)/g
`0-5
`:
`|
`-
`234.31°C|130
`-14
`!
`L
`a |
`L120
`
`224,59°C
`1.6315/g
`
`
`
`
`
`br 110 ©
`“100
`&
`L100 $
`|
`+90
`
`89
`
`L 7
`
`289.78°C
`
`> -24
`=
`re
`fe
`wi -3 4
`xr
`
`-4-
`
`ooooo60
`50
`75
`100
`125
`150
`175 200 225 250 275 300 325 350
`TEMPERATURE (°C)
`UNIVERSAL V2.4F TA
`EMD 68843 FORM III
`INSTRUMENTS
`Fig. 30
`
`Exo Up
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 16 of 23
`
`US 8,927,552 B2
`
`1
`
`0
`4
`
`-6
`
`-7
`
`-8
`
`
`
`235.88°C 288.30°C
`5.192)/g 133.1/g~~
`24291°C
`‘|
`nntypeA TT
`i
`
`
`
`G2
`=
`= 3
`g
`i -4
`fe
`Lu
`<= -5
`
`—7 150
`“ft
`= 140
`+130
`r
`}
`+120
`FO
`-110 &L
`.
` o
`+100 $
`[
`-90
`
`+80
`
`-70
`
`
`
`50
`
`75
`
`100
`
`125
`
`150
`
`60
`175 200 225 250 275 300 325 350
`
`290.59°C
`
`
`
`
`
`
`
`Exo Up
`
`TEMPERATURE(°C)
`EMD 68843 FORMIV
`Fig. 31
`
`UNIVERSALV2.4F TA
`INSTRUMENTS
`
`.
`
`\
`
`{ NL
`
`|
`\ |
`\
`i
`\
`\772.44°C
`
`0 5
`45.55 °C
`| 321.0J/g_------~boa
`_ wea
`Toho
`NS
`ON
`1
`a9 \
`3s?
`=
`= 7
`=
`6 -34
`i
`Kk
`wa
`|
`
`3.655%
`+ (0.3225mg)
`
`1
`
`|
`
`r
`
`170
`230.61°C 985.62°C
`5.872N/g
`113.21/
`+160
`Stpee g
`,
`°
`\ aee
`239.96°C \ L150
`1
`+140
`1]
`L
`i!
`L130
`\
`so
`!
`4
`+120
`F110 2
`=
`100
`L90
`
`|
`|
`
`-5-
`
`|
`
`-6
`
`Exo Up
`
`+80
`
`L70
`
`60
`TTTT T Tree T Tree
`T Tree T Tree T Tree
`T Tree T Tree T TIryt
`Tree T Tree T TIrrt T TITTrt
`50.
`75
`100
`125
`150
`175 200 225 250 275
`300 325 350
`TEMPERATURE(°C)
`UNIVERSALV2.4F TA
`INSTRUMENTS
`EMD 68843 FORM V (MONOHYDRATE)
`Fig. 32
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 17 of 23
`
`US 8,927,552 B2
`
`a
`
`17150
`
`108.4J/
`
`°
`
`Mer C
`57.94°C
`0-5
`ra
`Li9
`1 ee 141.45°C
`38.27J/g
`95.29°C
`6.190%
`(0.1924mg)
`
`a
`=
`=
`a
`—
`ie
`5
`=
`
`L140
`
`°
`
`L
`248.10°C
`+130
`0.8866//9 157e/g
`Hope I
`254.12°C \i
`|
`“------ 120
`OS
`|
`fr
`7
`L110 =
`1!
`L
`06
`1
`|
`UO
`UJ
`+100 =
`|
`=
`|
`
`
`
`
`
`
`50
`
`75
`
`100
`
`125
`
`150
`
`60
`175 200 225 250 275 300 325 350
`
`Exo Up
`
`TEMPERATURE(°C)
`
`EMD 68843 FORM VI(1.75 HYDRATE)
`
`NSYEOMENTS TA
`
`Fig. 33
`
`I>
`288,65°C
`,
`111.4J/g
`0
`|--—---=-------==HG
`Nu
`|
`-1
`i
`a |
`4
`!
`=
`= “2
`i
`1
`=
`|
`rs.
`-34
`be
`ui
`x=
`
`i
`I!
`!
`t
`
`sd
`
`-44
`
`|
`
`-54
`
`6
`
`°
`290.96°C
`
`50
`
`75
`
`100
`
`125
`
`150
`
`60
`175 200 225 250 275 300 325 350
`
`TEMPERATURE (°C)
`EMD 68843 FORM VII
`
`Fig. 34
`
`UNIVERSAL V2.4F TA
`INSTRUMENTS
`
`c150
`[
`L140
`L
`L130
`
`L120
`[4.2
`L110 =
`F-
`rs
`+100 5
`Lu
`L
`=
`+90
`L
`
`L8o
`
`L 40
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 18 of 23
`
`US 8,927,552 B2
`
`Toa
`
`64.80°C
`_5900/g
`mA /
`90.69°C
`
`17160
`274.92°C
`r
`8.976)/g
`L150
`267.93°C 1 984.72°C
`r
`___3857/9 1 119.7(149.3)J/g 140
`—~
`ST
`\\ 1 ae“
`\ \
`(7°
`WA
`oo &
`me
`pee
`272.68°C {|
`ros
`
`1
`L110 5
`/
`Lu
`t
`;
`Ss
`p 100
`
`aL
`
`rL
`
`90
`
`r8
`
`0
`
`!
`
`288.81°C
`
`
`ssOOO 70
`50
`75
`100
`125
`150
`175 200 225 250 275 300 325 350
`TEMPERATURE(°C)
`UNIVERSALV2.4F TA
`EMD 68843 FORM VIII (HEMIHYDRATE)
`'NSTRUMENTS
`Fig. 35
`
`1
`
`0+
`
`el
`=
`=
`© -2
`rs
`
`I -3
`
`4
`
`Sv
`
`Exo Up
`
`17150
`
`275.21°C
`
`!
`
`0
`
`
`4
`-2
`
`5
`
`-6
`
`-7
`
`Exo Up
`
`50
`
`75
`
`100
`
`125
`
`150
`
`60
`175 200 225 250 275 300 325 350
`TEMPERATURE (°C
`UNIVERSALV2.4F TA
`ae
`INSTRUMENTS
`EMD 68843 FORM IX
`
`Fig. 36
`
`
`
`
`
`p140
`566.80°C 5971/9
`
`40.86)
`281.54°
`nnernen ‘9 11711°1(146.0)1/g +130
`~ int
`/
`[
`a
`A
`L120
`=
`yi —
`
`S 3
`bl |
`Lii0=
`=
`271,87°C| |
`Ke
`g
`t a
`
` -4
`L100 5
`i
`lan
`
`
`=
`Loo
`
`
`
`L 8
`
`0
`
`,L
`
`70
`
`287.81°C
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 19 of 23
`
`US 8,927,552 B2
`
`0
`
`—-288.32°C
`932.13°C
`126.34°C
`-P
`:117.1/g_--
`6.804J/g
`99.424/9 |
`-1TE een\! fOPnnmeHhaot—“PS | eo
`‘4
`238.79°C |
`= 27
`|
`i
`\!
`i!
`S
`=]
`u
`|
`cS 3
`\
`=>
`i
`GS
`t
`°
`ir 4]
`f
`}130.71 C
`K
`6.288%
`
`Ir
`5
`(0.2979mg)
`I
`
`It
`-5-4
`|
`
`150
`
`140
`
`ah
`i
`[
`[ '3°
`+120
`6S
`tr
`L110 =
`FE
`+100 3
`=
`
`+90
`
`[
`30
`
`L70
`
`53°
`290.93°C
`
`
`
`
`60
`TTT
`TTT
`T
`TT T TIT T TIrrr T TTI T Tree T
`50.75 100
`125 150 175 200 225 250 275 300 325 350
`TEMPERATURE (°C
`UNIVERSAL V2.4F TA
`Cc)
`INSTRUMENTS
`EMD 68843 FORM XI (METHANOL SOLVATE)
`Fig. 37
`
`it/
`if
`
`-64
`
`To
`
`-8
`
`Exo Up
`
`05-5
`
`
`
`
`
`
`240.45°C 281.89°C 7
`0
`1.441J/g 110.05/g~~
`109.35°C
`Le4-47 Npnnnthfe“ts
`100.93°C
`251.73°C \ i
`-0.55
`S
`6.825J/g
`W
`1
`=
`ma
`{ot
`4
`|
`1.5
`|
`kK
`Lt
`a
`7
`I
`If
`li
`Y
`289.06°C
`
`1.367%
`(0.09074mg)
`
`-2.54
`
`
`
`+110
`
`[
`
`x
`_
`; 100 =
`a
`=
`
`l
`
`L90
`
`-3.5
`
`Exo Up
`
`50
`
`75
`
`150
`
`100
`
`125
`
`175 200 225 250 275 300 325 350
`TEMPERATURE (°C
`UNIVERSAL V2.4F TA
`(C)
`INSTRUMENTS
`EMD 68843 FORM XIV (n-heptane solvate)
`Fig. 38
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 20 of 23
`
`US 8,927,552 B2
`
`0
`
`150
`
`
`
`-1 225.63°C—-287.04°C114.50°C 140
`
`
`
`
`
`
`71.715/g
`12.46J/g
`109.1J/g
`a~~bettetoa 130
`=
`~
`235.04°C
`\t/
`139.84°C
`Vf
`go
`>
`MI
`= -3
`VT
`=
`|
`°
`1
`il
`L -4
`'
`H
`is
`
`13.55%
`f
`WW
`“5
`(1.044mg)
`¥
`
`6
`
`
`
`120
`
`<
`110 =
`ke
`x=
`100 &
`=
`90
`
`80
`
`290.24°C
`
`7
`
`70
`
`Exo Up
`
`
`-8 TTete T TTT T TTT T TITee T TTere T TTete T TTT.
`T TTT T TTee T TTere T TTere T TTete T TT
`T 60
`50
`75
`100
`125
`150
`175 200 225 250 275 300 325 350
`TEMPERATURE (°C)
`UNIVERSAL V2.4F
`EMD 68843 FORM XV (THF SOLVATE)
`[A INSTRUMENTS
`Fig. 39
`
`FORM XIV
`
`2.0
`
`1.5
`
`1.0
`
`
`
`0.5 ci
`
`0.0
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`t
`
`WAVENUMBER cm-1
`
`Fig. 40
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 21 of 23
`
`US 8,927,552 B2
`
`FORM XI
`
`2.0
`
`15
`
`1.0
`
`0.5
`
`nodetAMN 1 ld
`
`
`3500
`3000
`2500
`2000
`1 500
`1 000
`500
`WAVENUMBER cm-1
`
`Fig. 41
`
`i
`
`2.0
`
`FORMV
`
`|
`
`
`
`
`al dlapy
`
`Hal
`Se
`EP
`SAARIMhauteMWhhnat
`hw,
`0.0 cn
`3500
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`
`
`
`500
`
`ia
`
`0.5
`
`WAVENUMBER cm-1
`
`Fig. 42
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 22 of 23
`
`US 8,927,552 B2
`
`2.04
`
`15,
`
`FORMIV
`
`0.0Langa a K
`
`
`
`3500
`
`3000
`
`
`1.040.55
`Adu J
`
`
`2500
`
`1500
`2000
`WAVENUMBER cm-1
`
`1000
`
`Fig. 43
`
`FORM III
`
`2.04
`
`1.55
`
`1.0-
`
`0.5
`
`0.0——
`3500
`
`T
`3000
`
`2500
`
`2000
`
`1000
`
`T
`1500
`
`T
`500
`
`WAVENUMBER cm-1
`
`Fig. 44
`
`

`

`U.S. Patent
`
`Jan. 6, 2015
`
`Sheet 23 of 23
`
`US 8,927,552 B2
`
`FORM II
`
`3500
`
`3000
`
`2500
`
`2000
`
`1500
`
`1000
`
`WAVENUMBER cm-1
`
`Fig. 45
`
`2.04
`
`1.54
`
`FORM I
`
`2.0+ - eeee
` Mpls
`
`
`!4,
`|
`0.54
`0.0 JM _ilhghdlhil
`
`
`
`3500 3000+=2500 »=S«2000.~S—«1500~—=—«1000
`
`WAVENUMBER cm-1
`
`Fig. 46
`
`

`

`US 8,927,552 B2
`
`1
`POLYMORPHIC FORMSOF1-[4-(65-
`CYANOINDOL-3-YL)BUTYL]-4-@-
`CARBAMOYLBENZOFURAN-5-YL)
`PIPERAZINE HYDROCHLORIDE
`
`RELATED APPLICATIONS
`
`This application is a continuation application of U.S.
`patent application Ser. No. 13/085,117, filed Apr. 12, 2011,
`now U.S. Pat. No. 8,318,744, issued Nov. 27, 2012 whichis a
`continuation application of U.S. patent application Ser. No.
`12/566,835, filed Sep. 25, 2009, now U.S. Pat. No. 7,981,894,
`issued Jul. 19, 2011, which is a divisional application of U.S.
`patent application Ser. No. 12/110,704, filed Apr. 28, 2008,
`now U.S. Pat. No. 7,834,020, issued Nov. 16, 2010, which is
`a divisional application of U.S. patent application Ser. No.
`10/481,270,filed Dec. 19, 2003, now U.S. Pat. No. 7,381,726,
`issued Jun. 3, 2008, which is a national phase application of
`International Application No. PCT/EP02/006153, filed Jun.
`5, 2002, which claimspriority to European Patent Applica-
`tion No. 01113647.0, filed Jun. 19, 2001. The entire contents
`of each of the foregoing applications and patents are hereby
`incorporated by reference.
`
`FIELD OF THE INVENTION
`
`The present invention relates to novel compounds, to pro-
`cesses for preparing them andtotheir use in treating medical
`disorders.
`
`BACKGROUND OF THE INVENTION
`
`1-[4-(5-Cyanoindol-3-yl)butyl]-4-(2-carbamoy]-benzofu-
`ran-5-yl)-piperazine,
`its physiologically acceptable salts
`thereof (U.S. Pat. No. 5,532,241, column 7, lines 30 to 58), a
`process (U.S. Pat. No. 5,532,241, Example 4) by which
`it/they can be prepared andtheirusein treating certain medi-
`cal disorders are known from U.S. Pat. No. 5,532,241 and
`WO 00/72832.
`Example 4 of U.S. Pat. No. 5,532,241 describes the prepa-
`ration of 1-[4-(5 cyanoindol-3-yl)butyl]-4-(2-carbamoyl-
`benzofuran-5-yl)-piperazine hydrochloride by reacting 1-[4-
`(5-cyanoindol-3-yl)butyl]-4-(2-carboxybenzofuran-5-yl)
`piperazine
`at
`first with
`2-chloro-1-methylpyridinium
`methanesulfonate in N-methyl pyrrolidine and then with
`dried NH,. Customary working up gives the free base 1-[4-
`(5-cyanoindol-3-yl)butyl]-4-(2-carboxybenzofuran-5-yl)
`piperazine. 700 mgofthe base are dissolved in 30 ml 2-pro-
`panol under heating and then treated with 0.1n 2-propanolic
`HCL-solution (Merck-Art. No. 1.00326) until precipitation
`of hydrochloride is complete. The precipitate wasfiltered off
`and washed with diethylether and dried at room temperature
`to yield 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoy]-ben-
`zofuran-5-yl)-piperazine hydrochloride having a melting
`point of 289-272° C. There is no clear teaching elsewhere in
`the documentof any alternative route or modification to the
`process which would generate new crystal modifications of
`1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoy]-benzofuran-
`5-yl)piperazine hydrochloride or new solvates or hydrates of
`1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoy]-benzofuran-
`5-yl)-piperazine hydrochloride in different crystal modifica-
`tions.
` 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoy]-
`Former
`benzofuran-5-yl)-piperazine hydrochloride having a melting
`point of 269-272° C. was a mixture of amorphous 1-[4-(5-
`cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-
`piperazine hydrochloride, crystallized 1-[4-(5-cyanoindol-3-
`
`25
`
`30
`
`40
`
`45
`
`2
`yl)butyl]-4-(2-carbamoy]-benzofuran-5-yl)-piperazine
`hydrochloride and the free base 1-[4-(5-cyanoindol-3-yl)bu-
`tyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine.
`Certain crystalline, i.e. morphological forms of pharma-
`ceutical compounds maybeofinterest to those involvedin the
`development of a suitable dosage form because if the mor-
`phological form is not held constant during clinical andsta-
`bility studies, the exact dosage used or measured may not be
`comparable from onelot to the next. Once a pharmaceutical
`compoundis producedforuse, it is important to recognize the
`morphological form delivered in each dosage form to assure
`that the production process use the same form and that the
`same amountof drug is included in each dosage. Therefore, it
`is imperative to assurethat either a single morphological form
`or some known combination of morphological forms is
`present, in addition, certain morphological forms may exhibit
`enhanced thermodynamicstability and may be moresuitable
`than other morphological forms for inclusion in pharmaceu-
`tical formulations.
`
`SUMMARY OF THE INVENTION
`
`Methodsfor preparing pure crystals of 1-[4-(5-cyanoindol-
`3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine
`hydrochloride have now been found. Furthermore, surpris-
`ingly,
`1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-ben-
`zofuran-5-yl)-piperazine dihydrochloride, six (five+dihydro-
`chloride XII) new formsof 1-[4-(5-Cyanoindol-3-yl)buty]]-
`4-(2-carbamoy]-benzofuran-5-yl)piperazine hydrochloride,
`three new forms of 1-[4-(5-cyanoindol-3-yl)buty]|-4-(2-car-
`bamoyl-benzofuran-5-yl)-piperazine hydrochloride hydrate,
`six new formsofsolvates of 1-[4-(5-cyanoindol-3-yl)buty]]-
`4-(2-carbamoy]-benzofuran-5-yl)-piperazine hydrochloride
`and pure amorphous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-
`carbamoyl-benzofuran-5-yl)-piperazine hydrochloride have
`been found as have processes for their preparation. These
`forms are hereinafter referred to as I, II, II, IV, V, VI, VU,
`VI, IX, X, XI, XI, XIV, XV and XVI respectively.
`Throughout the specification, the term “Form”is generally
`used as a synonym for the term “modification”or “crystalline
`modification”.
`Accordingly, the present invention provides solvates of
`1-[4-(5-cyanoindol-3-yl)buty]]-4-(2-carbamoyl-benzofuran-
`5-yl)-piperazine hydrochloride in crystalline modifications
`and their use for the treatment and prevention of depressive
`disorders, anxiety disorders, bipolar disorders, mania,
`dementia, substance-related disorders, sexual dysfunctions,
`eating disorders, obesity, fibromyalgia, sleeping disorders,
`psychiatric disorders, cerebral infarct, tension, for the therapy
`of side-effects in the treatment of hypertension, cerebral dis-
`orders, chronic pain, acromegaly, hypogonadism, secondary
`amenorrhea, premenstrual syndrome and undesired puerperal
`lactation.
`The present invention furthermore provides 1-[4-(5-cy-
`anoindo]-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-pip-
`erazine hydrochloride hydrates in crystalline modifications
`and their use for the treatment and prevention of depressive
`disorders, anxiety disorders, bipolar disorders, mania,
`dementia, substance-related disorders, sexual dysfunctions,
`eating disorders, obesity, fibromyalgia, sleeping disorders,
`psychiatric disorders, cerebral infarct, tension, for the therapy
`of side-effects in the treatment of hypertension, cerebral dis-
`orders, chronic pain, acromegaly, hypogonadism, secondary
`amenorrhea, premenstrual syndrome and undesired puerperal
`lactation.
`Thepresent invention also provides 1-[4-(5-cyanoindol-3-
`yl)butyl]-4-(2-carbamoy]-benzofuran-5-yl)-piperazine
`
`

`

`US 8,927,552 B2
`
`3
`hydrochloride anhydrates in crystalline modifications and
`their use for the treatment and prevention of depressive dis-
`orders, anxiety disorders, bipolar disorders, mania, dementia,
`substance-related disorders, sexual dysfunctions, eating dis-
`orders, obesity, fibromyalgia, sleeping disorders, psychiatric
`disorders, cerebral infarct, tension, for the therapy of side-
`effects in the treatment of hypertension, cerebral disorders,
`chronic pain, acromegaly, hypogonadism, secondary amen-
`orrhea, premenstrual syndrome and undesired puerperal lac-
`tation.
`
`The present invention relates additionally to 1-[4-(5-cy-
`anoindol]-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-pip-
`erazine dihydrochloride in its crystalline modification andits
`use for the treatment and prevention of depressive disorders,
`anxiety disorders, bipolar disorders, mania, dementia, sub-
`stance-related disorders, sexual dysfunctions, eating disor-
`ders, obesity, fibromyalgia, sleeping disorders, psychiatric
`disorders, cerebral infarct, tension, for the therapy of side-
`effects in the treatment of hypertension, cerebral disorders,
`chronic pain, acromegaly, hypogonadism, secondary amen-
`orrhea, premenstrual syndrome and undesired puerperal lac-
`tation.
`
`The present invention relates additionally to pure amor-
`phous 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoy]-ben-
`zofuran-5-yl)-piperazine hydrochloride and its use for the
`treatment and prevention of depressive disorders, anxiety
`disorders, bipolar disorders, mania, dementia, substance-re-
`lated disorders, sexual dysfunctions, eating disorders, obe-
`sity, fibromyalgia, sleeping disorders, psychiatric disorders,
`cerebral infarct, tension, for the therapy of side-effects in the
`treatment of hypertension, cerebral disorders, chronic pain,
`acromegaly, hypogonadism, secondary amenorrhea, premen-
`strual syndrome and undesired puerperallactation.
`
`BRIEF DESCRIPTION OF THE FIGURES
`
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`
`1 is an IR absorption spectra of Form I
`2 is an IR absorption spectra of Form II
`3 is an IR absorption spectra of Form XV
`4 is an IR absorption spectra of Form XI
`5 is an IR absorption spectra of Form XIV
`6 is an IR absorption spectra of Form V
`7 is an IR absorption spectra of Form VI
`8 is an IR absorption spectra of Form VIII
`9 is an IR absorption spectra of Form IV
`10 is an IR absorption spectra of Form III
`11 is an IR absorption spectra of Form VII
`12 is an x-ray diffractogram of Form I
`13 is an x-ray diffractogram of Form I
`14 is an x-ray diffractogram of Form XV
`15 is an x-ray diffractogram of Form X
`16 is an x-ray diffractogram of Form XI
`17 is an x-ray diffractogram of Form XIV
`18 is an x-ray diffractogram of Form V
`19 is an x-ray diffractogram of Form VI
`FIG.20 is an x-ray diffractogram of Form VIII
`FIG.21 is an x-ray diffractogram of Form IV
`FIG. 22 is an x-ray diffractogram of Form III
`FIG.23 is an x-ray diffractogram of Form VII
`FIG. 24 is an x-ray diffractogram of Form IX
`FIG.25 is an x-ray diffractogram of Form XIII
`FIG.28 is an x-ray diffractogram of Form XVI
`FIG. 27is an energy/temperature diagram of FormsIT, TV
`and VII
`
`FIG.28 is a diagram of thermalanalysis of Form I
`FIG.29 is a diagram of thermal analysis of Form II
`FIG.30 is a diagram of thermal analysis of Form III
`
`10
`
`15
`
`20
`
`25
`
`30
`
`35
`
`40
`
`45
`
`50
`
`55
`
`60
`
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`FIG.
`
`4
`31 is a diagram of thermal analysis of Form IV
`32 is a diagram of thermal analysis of Form V
`33 is a diagram of thermal analysis of Form VI
`34 is a diagram of thermal analysis of Form VII
`35 is a diagram of thermal analysis of Form VIII
`36 is a diagram of thermal analysis of Form IX
`37 is a diagram of thermal analysis of Form XI
`38 is a diagram of thermal analysis of Form XIV
`39 is a diagram of thermal analysis of Form XV
`40 is a Ramanspectra of Form XIV
`41 is a Ramanspectra of Form XI
`42 is a Raman spectra of Form V
`43 is a Ramanspectra of Form IV
`44 is a Raman spectra of Form III
`45 is a Raman spectra of Form II
`46 is a Ramanspectra of Form I
`
`DETAILED DESCRIPTION OF THE INVENTION
`
`Ithas been foundthat1 -[4-(5-cyanoindol-3-yl)buty]]-4-(2-
`carbamoyl-benzofuran-5-yl)-piperazine hydrochloride
`is
`able to form solvates in crystalline modifications. Examples
`of such solvates include solvates from water, solvates from
`alcohols such as methanol, ethanol, propan-1-ol or propan-
`2-ol; solvates from organic esters such as ethyl acetate; sol-
`vates from nitriles such as acetonitrile; solvates from ketones
`such as acetone and butanone; solvates from ethers such as
`tetrahydrofuran and solvates from chlorinated hydrocarbons
`such as chloroform and solvates of hydrocarbons such as
`n-heptane or toluene. Preferred solvates are formed with
`polar solvents, preferably water, alcohols, organic esters,
`nitriles, ketones and ethers.
`Preferably, 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbam-
`oyl-benzofuran-5-yl)-piperazine hydrochloride forms sol-
`vates with acetone, tetrahydrofuran, methanol, ethyl acetate
`or n-heptane in crystalline modifications that means the
`bound solvent together with 1-[4-(5-cyanoindol-3-yl)butyl]-
`4-(2-carbamoy]-benzofuran-5-yl)-piperazine hydrochloride
`build the crystal structure. The molar ratio of the solvent to
`1-[4-(5-cyanoindol-3-yl)buty]]-4-(2-carbamoyl-benzofuran-
`5-yl)-piperazine hydrochloride could vary as known to
`skilled persons in the art. Preferably,
`the molar ratio is
`between 0.25:1 to 2.5:1, more preferably between 0.5:1 to
`1:1, most preferably 1:1. (n-heptan solvate 1/15:1)
`It should be understood that the present solvates of the
`invention may contain unbound water that is to say water
`whichis other than wafer of crystallization.
`Preferred forms of solvates of 1-[4-(5-cyanoindol-3-yl)
`butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydro-
`chloride include:
`
`a) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzo-
`furan-5-yl)-piperazine hydrochloride solvate with acetone in
`Form I; (as hereinafter defined)
`b) 1-[4-(5-cyanoindol-3-yl)buty1]-4-(2-carbamoyl-benzo-
`furan-5-yl)-piperazine hydrochloride solvate with tetrahy-
`drofuran in Form II; (as hereinafter defined)
`c) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzo-
`furan-5-yl)-piperazine hydrochloride solvate with tetrahy-
`drofuran in Form XV;(as hereinafter defined)
`d) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzo-
`furan-5-yl)-piperazine hydrochloride solvate with tetrahy-
`drofuran in Form X; (as hereinafter defined)
`e) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzo-
`furan-5-yl)-piperazine hydrochloride solvate with methanol
`in Form XI]; (as hereinafter defined)
`
`

`

`US 8,927,552 B2
`
`6
`Alternatively, Form I can be prepared according to a pro-
`cess which comprises:
`(1) suspending Form II of 1-[4-(5-cyanoindol-3-yl)butyl]4-
`(2-carbamoy]-benzofuran-5-yl)-piperazine hydrochloride,
`whichwill be described later in detail, in acetone
`(2) stirring at room temperature between a few hoursor days,
`preferably 10 to 20 days,
`(3) recovering the precipitated 1-[4-(5-cyanoindol-3-yl)bu-
`tyl]-4-(2-carbamoy]-benzofuran-5-yl)-piperazine hydro-
`chloride solvate with tetrahydrofuran byfiltration, and dry-
`ing in vacuo at room temperature.
`Form II according to the invention hasthe characteristic IR
`absorption spectra as shown in FIG.2 and the characteristic
`X-ray diffraction pattern as shown in FIG. 13. XRD pattern
`were recorded using a x-ray powderdiffractometer (Bruker
`AXS D5000) in transmission mode (Cu K alpha 1, PSD).
`IR absorption spectra were measuredin the spectral range
`4000-400 cm™' on a Bruker IFS48.Spectral resolution was 2
`cm’. The spectra as shownin the figures were converted to
`transmission.
`Form II can be further characterized with the aid ofthermal
`
`10
`
`15
`
`20
`
`5
`f) 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoy]-benzo-
`furan-5-yl)-piperazine hydrochloride solvate with n-heptane
`in Form XIV;(as hereinafter defined).
`Generally, the specific crystalline forms of the present
`invention have certain advantages over the product obtained
`according to U.S. Pat. No. 5,532,241. Amongothers, the most
`important advantagesare:
`reduced hygroscopicity,
`better compressibility during the tablating process,
`prolonged shelf life,
`better thermodynamic stability, i.e. stability against heat
`and humidity,
`better resistance to sunlight, i.e. UV-light,
`increased bulk density,
`improved solubility,
`bioavailability characteristics which are constant from one
`batch to the other,
`better flow and handling propertiesin the tableting process,
`improvedcolorstability,
`better filtration properties in the production process.
`Therefore, by use of the crystalline forms of the present
`invention, it is possible to obtain galenic formulations having
`improved homogenicity, stability, purity and uniformity from
`one batch to the other.
`
`Form I according to the invention has the characteristic IR
`absorption spectra as shown in FIG. 1 and the characteristic
`X-ray diffraction pattern as shown in FIG. 12. XRD pattern
`were recorded using a x-ray powderdiffractometer (Bruker
`AXS D5000) in transmission mode (Cu K alpha 1, PSD).
`IR absorption spectra were measuredin the spectral range
`4000-400 cm7' on a Bruker IFS48. Spectral resolution was 2
`cm”’. Sample preparation was performed generally as KBr
`disk. The spectra contains additionally a specific acetone
`absorption band at 1709 em7’.
`Form I can be further characterized with the aid of thermal
`
`25
`
`35
`
`40
`
`45
`
`analysis measured in the range of 30° to 350° C. FIG. 29
`shows the DSC (TA Instruments DSC 2920) and TGA (TA
`instruments TGA 2950) measurements. Form II showsa des-
`olvation process between 120° C. and 180° C. Analysis by
`thermogravimetry showedthe presence of 13 weight-% to 14
`weight-% ofTHF(theory of 1:1 solvate 13.11 weight-%). The
`DSC measurement gives a phase transition to form VII
`between 200° C. and 260°